We want to become the undisputed leader in delivering Microbiome Ecosystem Therapies to treat moderate to severe dysbiosis in patients by mastering different modalities.
Building a leading microbiome company in oncology
We restore and modulate patient-microbiome symbiosis
to improve survival in cancer.
Our vision
Our mission
We aim to develop, commercialize, and license innovative Microbiome medicines for patients with severe oncology diseases, using our full ecosystem modalities, on a global basis.
Our team
Siân joined MaaT Pharma in 2016 as a CFO. She is now COO/CFO and focuses on the finances and general operations management at the company. In the past, she held various finance roles, including 7 years as Principal Financial Officer and Director at Avadel Pharmaceuticals (AVDL) where she was involved in a capital raise of $130 million. Siân started her career at EY.
CPA, IFRS Certified
Savita joined MaaT Pharma in May 2020 as Chief Business Officer. Prior to joining the company, Savita was the Director of Strategic Marketing and Corporate Communications, Business Development at ADOCIA. She held various roles in Business Development and Marketing at e(ye)BRAIN, a medical device company dedicated to the early diagnosis of neurological disease and worked as a Consultant for the Healthcare Industry at E&Y.
PhD in neuroscience, MBA
Hervé Affagard is the CEO and founder of MaaT Pharma. For the past 15 years, Hervé has been an intra/entrepreneur in the healthcare industry, after starting his career in IT in the steel industry. He founded MaaT Pharma in late 2014 together with onco-hematologist Prof. Mohammad Mohty and microbiologist Dr. Joël Doré, after a professional career that spanned multiple industries. Hervé has led MaaT Pharma’s development from its early concept in 2013 and has been at the forefront of the development of the microbiome healthcare ecosystem in France and Europe. Hervé is also a board member for the French biotech industry association, France Biotech and an active contributor to Allliance Promotion Microbiote, an organization recently founded to support the microbiome sector development in France.
Engineer, MBA,
John joined MaaT Pharma as CMO in July 2020, to run the clinical development programs for the company’s microbiome ecosystem therapies products, targeted at the treatment of liquid and solid tumors. He brings 25 years of experience in the pharmaceutical industry and a strong expertise in microbiome-based therapeutic development and immune modulation.
Prior to joining Maat Pharma, John has held various senior positions at Veloxis Pharmaceuticals, Novartis Pharmaceuticals and Enzon Pharmaceuticals, gaining a breadth of international experience in clinical development of various oncology, hematology and transplantation therapeutics in both the USA and Europe. He has developed and launched multiple drugs in oncology, immune diseases and transplantation.
MD, MBA
Carole is the Chief Technology Officer at MaaT Pharma and has led MaaT Pharma’s pharmaceutical development activities since 2014. She brings 20 years of experience in the pharmaceutical industry, having previously held multiple responsibilities in cGMP manufacturing at Biorad and has been in charge of operations for a start-up company specializing in glycosylated proteins. She is the co-author of 7 published patents and 7 scientific publications.
PhD in microbiology, Engineer in Agronomy, Genetics and Biotechnology
Isabelle joined the MaaT Pharma in November 2020 as Chief of Staff. She is in charge of special projects to support the CEO based on strategic priorities, as well as the Quality and IP teams. Isabelle brings more than 25 years of experience in the pharmaceutical industry. Prior to joining MaaT Pharma, Isabelle had been an independent consultant for Institut Pasteur and SmartImmue, VP Operations as Voisin Consulting and held several executive positions at GSK and Bristol-Myers Squibb.
Pharm D, MBA
Our GvHD-focused Scientific Advisory Board
Dr. Ernst Holler was Director of the Clinical and Experimental Allogeneic Stem Cell Transplant Program in the Department of Internal Medicine at the University of Regensburg, Germany, for more than 20 years and is now Senior Professor on Translational Research in GvHD.
With more than 250 peer-reviewed manuscripts to his name, he is an expert in the field of Graft-vs-Host-Disease and was awarded the Van Bekkum Award, the highest award from the European Society for Stem Cell Transplantation.
Dr. Florent Malard is a hematologist at the Hospital Saint-Antoine and an Associate Professor at Sorbonne University in Paris, France. His research interests were clinical and translational studies on allogeneic hematopoietic stem cell transplantation, with a particular focus on preclinical studies on graft-versus-host disease. He joined Dr. van den Brink’s laboratory to study thymopoiesis reconstitution after thymic injury, particularly after allogeneic hematopoietic stem cell transplantation.
His research includes clinical and translational studies on allogeneic hematopoietic stem cell transplantation with a particular focus on preclinical studies on GvHD and has published over 100 peer-reviewed manuscripts.
His research includes clinical and translational studies on allogeneic hematopoietic stem cell transplantation with a particular focus on preclinical studies on GvHD and has published over 100 peer-reviewed manuscripts.
Doctor Mohamad Mohty is Professor of Haematology, and head of the Haematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University (Paris, France). He also leads a translational research team (INSERM team) at the Saint-Antoine Research Center, Paris, France. He has always been a key figure of the EBMT and in the stem cell transplant and cellular therapy field. Over the past 25 years or so, Professor Mohty has been a very active member of the EBMT.
He has published over 600 peer-reviewed articles internationally, and lectured in more than 70 countries.
In 2021, Professor Mohty has been nominated a “Chevalier de la Légion d’Honneur”, the highest French award, and one of the world’s most widely recognised decorations.
MD, PhD
Pr. Eric Pamer, a Donald F. Steiner Professor, Departments of Medicine, Microbiology, and Pathology and Director, Duchossois Family Institute, focuses his research on the impact of the intestinal microbiota on resistance to Vancomycin-resistant Enterococcus faecium, Clostridium difficile and Klebsiella pneumoniae infections in patients receiving cancer treatment, with a specific focus on highly immunocompromised patients undergoing allogeneic hematopoietic stem cell transplantation.
Prof. Dr. Robert Zeiser is Head of the Tumor Immunology and Immune Modulation at the Medical Center of the University of Freiburg in Germany. His research and treatment focus on acute leukemia, malignant melanoma, tumor cell migration, allogeneic hematopoietic stem cell transplantatio, and functional imaging. Professor Zeiser is the winner of the Artur Pappenheim Prize 2014 of the German Society for Hematology and Medical Oncology (DGHO) and the Richtenhain Prize 2016 of the German Cancer Research Center.
Joël is a worldwide renowned researcher with more than 200 publications relating to the Host/Microbiome interaction. Joël Doré is a research director in the Joint Research Unit for Food and Gut Microbiology for Human Health and scientific director of the MetaGenoPolis, both of which are part of INRA Île-de-France – Jouy-en-Josas and brings more than 30 years of research in the Microbiome field. Now one of the most cited scientists in the world (HiCiSci), he began his research on animals.
PhD
Dr. Jenq is currently an assistant professor at MD Anderson Cancer Center, in the Departments of Genomic Medicine and Stem Cell Transplantation. His research aims to improve outcomes for patients undergoing hematopoietic cell transplantation, with a particular focus on the intestinal microbiota and how changes in the composition of intestinal bacterial commensals can impact on clinical outcomes.
MD
MD
Dr. Peled is a medical oncologist at the Memorial Sloan Kettering Cancer Center. Dr Peled specializes in bone marrow transplantation for blood cancers including leukemias, multiple myeloma, myelodysplastic syndrome, and lymphoma.
He studies how the intestinal microbiota interact with the host immune system as it relates to hematopoietic stem-cell transplantation, with a particular interest in graft-vs-tumor activity and graft-vs-host disease.
His long-term research goals include developing microbiota-based biomarkers that will be clinically useful in the care of transplant recipients, as well as microbiota-targeted therapeutic strategies to improve patient outcomes.
Our Board of Directors
Jean-Marie has been President and CEO of Biocodex. He steered the creation of the “Biocodex Microbiota Institute” supporting innovative projects from Microbiota researchers. Jean-Marie has a long-track record of CEO positions amongst international firms such as LVMH or Bongrain.
Engineering degree Ecole Centrale Paris, MBA from Insead
Claude joined MaaT Pharma as a board member in July 2020. Since 2017, Claude has held the position of Executive Vice President of R&D and Chief Scientific Officer at Servier. He brings decades of high-level leadership in pharmaceutical R&D, having previously served as Executive Vice-President of R&D at Ipsen Pharma and as Global Senior Vice President for Respiratory & Inflammation Research Area at AstraZeneca. His career also includes senior positions at Novartis, Roche and Pfizer.
PharmD, PhD
Isabelle de Crémoux is CEO and Managing Partner of Seventure Partners and leads the Life Sciences team. She joined Seventure in 2001 to establish the Life Sciences division. Isabelle supervises the Life Sciences business and personally invests in French and Scandinavian and north American biotech, nutrition, healthcare, personalized medicine. Isabelle has a particular interest in the microbiome field and frequently gives lectures at conferences in this domain. As a visionary, she launched Health for Life Capital™, the first European investment vehicule to support the microbiome revolution. Prior to joining Seventure Partners, she worke at Arthur Andersen/ EY, Pfizeer and Laboratoires Fournier.
Engineering degree from Ecole Centrale Paris
Hervé Affagard is the CEO and founder of MaaT Pharma. For the past 15 years, Hervé has been an intra/entrepreneur in the healthcare industry, after starting his career in IT in the steel industry. He founded MaaT Pharma in late 2014 together with onco-hematologist Prof. Mohammad Mohty and microbiologist Dr. Joël Doré, after a professional career that spanned multiple industries. Hervé has led MaaT Pharma’s development from its early concept in 2013 and has been at the forefront of the development of the microbiome healthcare ecosystem in France and Europe. Hervé is also a board member for the French biotech industry association, France Biotech and an active contributor to Allliance Promotion Microbiote, an organization recently founded to support the microbiome sector development in France.
Engineer, MBA,
Muriel Prudent is an Investor at Bpifrance, French public investment bank, managing a portfolio of health- and other deeptech startups within the PSIM Fund, which focuses on major tech disruptions.
Graduated from HEC Paris and Bocconi University in Milan
Graduated from HEC Paris and Bocconi University in Milan
Engineer ENSIA, MBA in Finance and Accounting
Jérôme is Director of Healthcare Activites at Credit Mutuel Innovation. Throughout his career, he worked on more than 30 investments/refinancings (mainly in the healthcare industry), sat on the executive (or supervisory) board of most of the companies featured in his portfolio, and participated in3 IPOs.
Graduate degrees in Immunology, Dual-Expertise (AMU) & Executive MBA, IAE Aix
Our history
-
2014
Incorporation of MaaT Pharma, based on INRAE technology
-
2015
In vitro and preclinical validation
+70% Reconstruction of the gut microbiota achieved, dose determination -
2016
Inauguration of the first GMP- compliant platform
€10 Million Serie A Financing Round
Proof of Concept Study (ODYSSEE) First AML patient treated with autologous FMT -
2017
Development of high richness and diversity pooled products
Partnerships with Biocodex and Bioaster
-
2018
Initiation of Phase II (HERACLES): MaaT013 in steroid refractory gastro-intestinal aGVHD patients after Allogenic HSCT
ODYSSEE Study showed 90% reconstruction in 25 patients
Proprietary medical device system received CE mark -
2019
Patent Portfolio expansion with 3 granted patents
MaaT013 Initial Early Access Program (EAP1) data presented at ASH -
2020
Series B completed
Additional EAP data presented
Initiation of Phase I (CIMON): MaaT033 in hematology malignant Patients Under intensive Chemotherapy
Partnership with AP-HP -
2021
Announced positive HERACLES data
Presented additional EAP data
Several positive DSMB decisions for CIMON
